Archived Facts

Posts Tagged ‘clinical’

Tucson, AZ (PRWEB) September 10, 2012

Critical Path Institute and CDISC (Clinical Data Interchange Standards Consortium) announce the availability of a breakthrough tool to help combat tuberculosis (TB)a persistent disease resulting in 1.7 million deaths globally each year.

This new toola standardized way to report research datais critical for advancing new TB drug regimens. For the first time, researchers are able to combine and evaluate data from multiple studies using a common approach. This will help accelerate the development of new TB drugs by enhancing the design of clinical trials and the evaluation of new drugs. The TB data standards will also assist the regulatory review process for new drug development tools, such as clinical trial simulation models and methods to evaluate treatment endpoints.

The scope of this project was immense and its delivery in nine months was made possible by the smooth collaboration among C-Path, CDISC, FDA, industry partners and the many volunteers who participated in this effort through the Critical Path to TB Drug Regimens initiative, says Dr. Carolyn Compton, President and CEO of Critical Path Institute.

The Critical Path to TB Drug Regimens (CPTR) initiative is a global collaboration among pharmaceutical companies, academia, patient advocacy groups, and regulatory bodies having the shared goal of accelerating the development of new drug regimens targeting TB.

A tremendous amount of innovation has enabled an exciting new era of TB drug development, says Dr. Mel Spigelman, President and CEO, TB Alliance. To support a regimen-based development approach, the research and regulatory communities need new standards and platforms to help conduct, submit, and review this work. This new standard is an example of such a tool and will benefit both researchers and regulators, ultimately helping to ensure new TB cures reach those who need them as quickly as possible.

TB Standards/2

The U.S. Food and Drug Administration (FDA) has identified TB as one of several disease areas having a critical need for data standards. CDISC is very pleased to have had the opportunity to collaborate with the FDA, Bill & Melinda Gates Foundation, Global Alliance for TB Drug Development, and C-Path to complete this TB standard work, based in part on preliminary work conducted through a National Institutes of Health Roadmap grant and clinical terminology support provided through our partnership with the National Cancer Institutes Enterprise Vocabulary Services, says Bron Kisler, VP, Strategic Initiatives and CDISC lead on the project. CDISC standards are vendor-neutral, platform independent, and publically available through the CDISC website at http://www.cdisc.org/therapeutic.

Future CDISC therapeutic area data standards will be developed under the leadership of CFAST (Coalition For Accelerating Standards and Therapies), a joint endeavor between C-Path and CDISC to accelerate clinical research and medical product development by creating and maintaining data standards, tools, and methods for conducting research in therapeutic areas important to public health.

ABOUT CRITICAL PATH INSTITUTE (C-PATH): Established in 2005 as a non-profit organization, C-Path was formed with public and private philanthropic support from the University of Arizona, the US Food and Drug Administration (FDA), and the Tucson community. Additional funding has been provided by Science Foundation Arizona (SFAz). C-Path is committed to improving human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. An international leader in forming collaborations around this mission, C-Path has established global, public-private partnerships that include more than 1,000 scientists from government regulatory agencies, academia, patient advocacy organizations, and 41 major pharmaceutical companies. C-Path has headquarters in Tucson, AZ and an office in Rockville, MD. For more information, visit http://www.c-path.org and follow us on Facebook.

ABOUT CDISC

CDISC is a 501(c)(3) global non-profit charitable organization, with nearly 300 supporting member organizations from across the clinical research and healthcare arenas. Through the efforts of volunteers around the globe, CDISC catalyzes productive collaboration to develop industry-wide data standards enabling the harmonization of clinical data and streamlining research processes from protocol through analysis and reporting, including the use of electronic health records to facilitate the collection of high quality research data. The CDISC standards and innovations can decrease the time and cost of medical research and improve quality, thus contributing to the faster development of safer and more effective medical products and a learning healthcare system. The CDISC Vision is to inform patient care and safety through higher quality medical research.







Incoming search terms:

Related Posts:

Advanced Health Assessment & Clinical Diagnosis in Primary Care, 4e

Advanced Health Assessment & Clinical Diagnosis in Primary Care, 4e

Designed for advanced practice nurses and advanced practice nursing students, as well as Physician’s Assistant students and practitioners, Advanced Health Assessment & Clinical Diagnosis in Primary Care, 4th Edition, is a practical resource that takes you to the “next step” of health assessment, beyond basic history and physical examination and through the diagnostic reasoning process. Accessible and concise, it approaches physical examination by focusing on a specific chief complaint rather than a diagnosis of a disease entity. Each chapter is organized into four major areas: Focused History; Focused Physical Examination; Laboratory and Diagnostic Studies; and Differential Diagnosis. Those who master the diagnostic reasoning process in this text will be able to accurately diagnose the majority of conditions they will see in clinical practice.

  • Easy-to-follow format with consistent organization improves your ability to understand and accurately perform the different elements of the diagnostic reasoning process:
    • Focused History sections walk you through the thinking process involved in obtaining a pertinent, relevant, problem-specific history that will assist in differential diagnosis.
    • Key Questions highlight what questions to ask the patient, followed by an explanation of what the patient’s responses might signify, to guide you toward an accurate assessment and precise diagnosis.
    • Focused Physical Examination sections explain how to conduct more advanced diagnostic techniques and offer interpretations of the findings.
    • Laboratory and Diagnostic Studies sections give a brief outline of what types of laboratory or diagnostic studies would be appropriate for the chief complaint or suspected diagnosis.
    • Differential Diagnosis sections contain the most common differential diagnoses for each chief complaint and summarize the history and physical examination findings, along with the laboratory and diagnostic studies indicated.
  • Differential Diagnosis tables offer an at-a-glance summary of possible diagnoses.
  • Reordered table of contents, organized alphabetically by patient problem rather than by body system, simplifies and accelerates information retrieval. A list of chapters by body system is also included for reference.
  • Three new chapters:
    • Chapter 23: Palpitations
    • Chapter 36:¬†Weight Loss/Gain (Unintentional)
    • Chapter 38: The Abdominal X-ray
  • Additional Evidence-Based Practice boxes provide additional research-based tips on conducting the most effective exams for more accurate diagnoses.

List Price: $ 73.95

Price: $ 54.89

Related Posts:

Bristol, UK (PRWEB UK) 2 April 2012

Duport Associates have discovered that 25 new companies were formed in February 2012 with the word clinical as part of their company name, up from a previous high of 21 in March 2003.

This new rise coincided with the controversial Health and Social Care Bill making its way through parliament, as many companies and organisation see new opportunities in the health industry.

The new interest in clinical companies just goes to show that many businesses are hoping to get more involved in providing healthcare services to the public and to the NHS, said Peter Valaitis, Managing Director of Duport Associates.

But the rise of so many new clinical company formations could also be part of a new emphasis on science and scientific research used by a wide range of industries including fitness, beauty and food.

The word ‘clinical’ automatically makes you think of cleanness, scientific excellence and cold hard facts, so its a great term to use if you want that to be peoples first impression of your business or your products, Peter added.

As well as healthcare organisations, companies such as cleaners and caterers can also benefit from being thought of as clinical, as the emphasis on this medical term can help build an expectation of a more thorough service. This can also be a huge boon if your company hopes to get contracts with the NHS, schools or medical units.

With the Health and Social Care Bill now approved, there may be more companies seeking to be thought of as clinical and suitable to work alongside the NHS, and it is possible that this record high becomes a sustained increase over the next few months.

Duport Associates Ltd is a leading UK company formation agent, operating in the UK for around 15 years. Duport registers around 10,000 new companies each year using its Companies House approved software. The Company Register which is maintained by Companies House contains public information about Limited companies and directors.





Related Posts:

Yorba Linda, CA (PRWEB) March 28, 2012

BioConference Live, the world’s largest producer of online-only conferences, is bringing together the clinical diagnostics community for this groundbreaking virtual conference that kicks off Wednesday May 23rd at 10:00 AM Eastern Standard Time. The conference will continue for two days through Thursday May 24th at 10:00 PM Eastern Standard Time. This is a Continuing Education program accredited by the AACC ACCENT, so attendees can earn free CE Credits.

BioConference Live features live, video keynote presentations where attendees can have their questions answered by presenters in real time. The event features a virtual exhibit hall and a networking lounge to interact with world renowned experts and colleagues. BioConference Live is conveniently held online for free, and is easily accessed from any computer, making it time efficient and cost effective to attend. Participants will be able to:


Search and attend session(s) of their choice
Have their questions answered in real-time by experts via live videos
Receive Free Continuing Education Credits accredited by the AACC ACCENT
Chat live with peers and speakers
Browse a virtual exhibit floor for solution providers

BioConference Live will bring together clinicians, doctors, medical experts, lab directors and professionals from around the world to learn about recent advances in clinical diagnostics. The topics of the 2012 conference consist of Infectious Disease, Oncology, Vitamin D, Cardiology, Nutrition, Laboratory Testing, Clinical Chemistry, Molecular Diagnostics, Diabetes, Point of Care, Allergy, Hematology, and much more. Speakers include:

Michael Dugan, MD, Chief Medical Officer, Roche Molecular Diagnostics
Marc Redman, MBA, Vice President – Chemistry & Immunoassays, Diagnostics Division, Siemens Healthcare
Robert Hamilton, PhD, DABMLI, Professor of Medicine and Pathology, Johns Hopkins University School of Medicine, Director, Johns Hopkins Dermatology, Allergy and Clinical Immunology Reference Laboratory
Bruce Hanna, PhD, Clinical Professor of Pathology and Microbiology, NYU School of Medicine
Hubert Vesper, PhD, Chief of CDC Protein Biomarker Lab, Division of Laboratory Sciences, National Center for Environment, Centers for Disease Control and Prevention
Seth Martin, MD, Cardiology Fellow, Division of Cardiology, The Johns Hopkins Hospital
Paul Billings, MD, PhD, Chief Medical Officer, Life Technologies
Cynthia Bowman, MD, Anatomic and Clinical Pathologist, Currently Chair of CAP POCT Committee
Howard Weintraub, MD, Clinical Director of Center for the Prevention of Cardiovascular Disease, Clinical Associate Professor, New York University
Joseph Coresh, MD, PhD, Professor, Director, Cardiovascular Epidemiology & Comstock Center, Johns Hopkins University, Bloomberg School of Public Health
Paul Epner, MEd, MBA, Director, The Society to Improve Diagnosis in Medicine, Principal, Paul Epner LLC
Franco Folli, MD, PhD, Professor of Medicine, Division of Diabetes, UT Health Science Center at San Antonio
George Fritsma, MS, MT (ASCP), Teacher and Lab Practitioner, Fritsma Factor, Precision BioLogic, Associate Professor, Department of Pathology, University of Alabama at Birmingham
Wieslaw Furmaga, MD, Associate Professor, University of Texas Health Science Center at San Antonio, Pathology, Interim Medical Director, Molecular Reference Laboratory, Pathology
Eric Gluck, MD, JD, Director of Critical Care Services, Swedish Covenant Hospital
William Grant, PhD, Director, Sunlight, Nutrition and Health Research Center (SUNARC)
David Grenache, PhD, Medical Director, Special Chemistry Laboratory, Associate Professor of Pathology, University of Utah School of Medicine, ARUP Laboratories
Michael Holick, MD, PhD, Professor of Medicine, Physiology and Biophysics, Director of the General Clinical Research Center, Director of the Vitamin D, Skin and Bone Research Laboratory, Director, Biologic Effects of Light Research Center, Boston University Medical Center
Brian Jackson, MD, Associate Professor of Pathology (Clinical), Medical Director of Informatics, ARUP Laboratories, University of Utah, Department of Pathology
Steven Jones, MD, Director, Inpatient Cardiology, Assistant Professor of Medicine, Cardiology, Johns Hopkins Medicine
Allan Laurence Kennedy, MD, FRCP, Department Chair, Endocrinology, Diabetes and Metabolism, Cleveland Clinic
Gerald Kost, MD, PhD, MS, FACB, Professor, Director of Clinical Chemistry , Director, POCTCTR, School of Medicine, University of California, Davis, Director and PI, Point-of-care technologies Center, National institute of biomedical imaging and bioengineering, NIH
Matthew Krasowski, MD, PhD, Vice Chair of Clinical Affairs, University of Iowa Hospitals and Clinics, Department of Pathology
George Kudolo, PhD, Professor, Clinical Chemistry & Toxicology, University of Texas Health Science Center, Clinical Lab Sciences
Michael Laposata, MD, PhD, Director, Division of Laboratory Medicine and Clinical Laboratories, Edward and Nancy Fody Professor, Vanderbilt University
Kent Balanis Lewandrowski, MD, Pathologist, Associate Chief for Clinical Services, Massachusetts General Hospital
Randie Little, PhD, Associate Professor, Diabetes Diagnostic Laboratory, Dept. of Pathology & Anatomical Science, University of Missouri School of Medicine
Hans Loyda, PhD, Director, Clinical Development and Education, Roche Diagnostics
Giuseppina Maccarrone, PhD, Research Scientist, RG. Proteomics and Biomarkers, Max Planck Institute of Psychiatry
Gwendolyn McMillin, PhD, Associate Professor (Clinical), University of Utah Pathology, Medical Director, Associated Regional , Clinical Drug Abuse Testing, Medical Director, ARUP Laboratories, Trace Elements, Co-Medical Director, ARUP Laboratories, Pharmacogenomics
Pieter Muntendam, MD, Executive Vice President, Chief Medical Officer, BG Medicine, Inc.
James Nichols, PhD, Medical Director, Clinical Chemistry, Baystate Health, Professor of Pathology, Tufts University Scho, Tufts University School of Medicine, Baystate Health
Liron Pantanowitz, MD, Director of the Pathology Informatics Fellowship Program, Director of the FNA Clinic, Assistant Director of Cytology in the Division of Cytology at UPMC-Shadyside, Associate Professor, Pathology & Biomedical Informatics, U of Pittsburgh Medical Center, Editor-in-Chief, Journal of Pathology Informatics
Ellinor Peerschke, PhD, FAHA, Vice Chair, Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center
Christopher Price, PhD, Visiting Professor in Clinical Biochemistry, University of Oxford
Andrea Rose, PhD, MBA, Senior Clinical Support Consultant, Clinical Support, Roche Diagnostics
Kevin Rosenblatt, MD, PhD, Associate Professor, Center for Proteomics and Systems Biology, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston (UTHealth)
Erkki Ruoslahti, MD, PhD, Distinguished Professor, University of California, Santa Barbara, Sanford-Burnham Medical Research Institute (at UCSB), Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla
Mark Shirtliff, PhD, Associate Professor, Department of Microbial Pathogenesis, Dental School, Associate Professor, Dept. of Microbiology and Immunology, School of Medicine, University of Maryland School of Medicine
Wilson Tang, MD, Staff Cardiologist and Research Director, Sydell and Arnold Miller Family Heart & Vascular Institute, Associate Professor of Medicine, Lerner College of Medicine of Case Western Reserve University, Director, Cardiomyopathy Program, Cleveland Clinic
Yi-Wei Tang, MD, PhD, F(AAM), FIDSA, Chief of the Clinical Microbiology Service, Department of Laboratory Medicine, Memoria

Incoming search terms:

Related Posts:

Chinese drugmaker Sihuan Pharmaceutical Holdings Group Ltd has registered its anti-hypertensive drug with the country’s drug regulator and hopes to obtain approval to begin clinical trials in China by the end of 2013.

Incoming search terms:

Related Posts:

GE Healthcare this morning said it plans to acquire clinical cancer-testing company Clarient for around $580 million in an effort to expand GE’s footprint in the molecular cancer-testing and pharmacogenetic-testing markets. …

Read this article:
GE Healthcare's Bid to Acquire Clarient Could Alter Clinical …

Incoming search terms:

Related Posts:

As a registered dietitian with a clinical background and a single mother, of course my concerns for Michigan center on health care and how myself and the general public are and will be affected by health care reform. The new Michigan governor has the potential to influence the current state of high-cost, health care in Michigan.

Here is the original post:
How the Michigan Governor’s Race Affects Me: A Single Mother and Registered Dietitian

Related Posts:

Shares of Geron Corp. rose after the company said it started a clinical trial on its embryonic stem cell therapy aimed at spinal cord injuries.

Go here to see the original:
Geron shares rise on stem cell study

Related Posts:

U.S. doctors have begun treating the first patient to receive human embryonic stem cells, but details of the landmark clinical trial are being kept confidential, Geron said Monday.

View post:
First Patient Treated in Geron Stem Cell Trial

Related Posts:

U.S. doctors have begun treating the first patient to receive human embryonic stem cells, but details of the landmark clinical trial are being kept confidential, Geron said Monday.

Link:
First Patient Treated in Geron Stem Cell Trial

Related Posts: